CL2016002318A1 - Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. - Google Patents
Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.Info
- Publication number
- CL2016002318A1 CL2016002318A1 CL2016002318A CL2016002318A CL2016002318A1 CL 2016002318 A1 CL2016002318 A1 CL 2016002318A1 CL 2016002318 A CL2016002318 A CL 2016002318A CL 2016002318 A CL2016002318 A CL 2016002318A CL 2016002318 A1 CL2016002318 A1 CL 2016002318A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical composition
- liquid carrier
- oral dosage
- dosage form
- solution
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 6
- 239000007788 liquid Substances 0.000 title abstract 4
- 239000006186 oral dosage form Substances 0.000 title abstract 3
- 150000001298 alcohols Chemical class 0.000 title abstract 2
- 229960002639 sildenafil citrate Drugs 0.000 title abstract 2
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 title abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title abstract 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 abstract 4
- 229960003310 sildenafil Drugs 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 239000006193 liquid solution Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01Q—ANTENNAS, i.e. RADIO AERIALS
- H01Q5/00—Arrangements for simultaneous operation of antennas on two or more different wavebands, e.g. dual-band or multi-band arrangements
- H01Q5/50—Feeding or matching arrangements for broad-band or multi-band operation
- H01Q5/55—Feeding or matching arrangements for broad-band or multi-band operation for horn or waveguide antennas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01Q—ANTENNAS, i.e. RADIO AERIALS
- H01Q1/00—Details of, or arrangements associated with, antennas
- H01Q1/27—Adaptation for use in or on movable bodies
- H01Q1/28—Adaptation for use in or on aircraft, missiles, satellites, or balloons
- H01Q1/288—Satellite antennas
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01Q—ANTENNAS, i.e. RADIO AERIALS
- H01Q1/00—Details of, or arrangements associated with, antennas
- H01Q1/36—Structural form of radiating elements, e.g. cone, spiral, umbrella; Particular materials used therewith
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Astronomy & Astrophysics (AREA)
- Remote Sensing (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Aviation & Aerospace Engineering (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461955299P | 2014-03-19 | 2014-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016002318A1 true CL2016002318A1 (es) | 2017-03-24 |
Family
ID=54145440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016002318A CL2016002318A1 (es) | 2014-03-19 | 2016-09-14 | Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9968609B2 (instruction) |
| EP (2) | EP3119201B1 (instruction) |
| JP (1) | JP6744821B2 (instruction) |
| KR (1) | KR20160137584A (instruction) |
| CN (1) | CN106132204B (instruction) |
| AU (2) | AU2015233006B2 (instruction) |
| CA (1) | CA2942628C (instruction) |
| CL (1) | CL2016002318A1 (instruction) |
| CY (1) | CY1120187T1 (instruction) |
| DK (1) | DK3119201T3 (instruction) |
| EA (1) | EA032819B1 (instruction) |
| ES (1) | ES2668915T3 (instruction) |
| HR (1) | HRP20180773T1 (instruction) |
| HU (1) | HUE038431T2 (instruction) |
| IL (1) | IL247840B (instruction) |
| LT (1) | LT3119201T (instruction) |
| MX (1) | MX371276B (instruction) |
| NO (1) | NO2723977T3 (instruction) |
| PL (1) | PL3119201T3 (instruction) |
| PT (1) | PT3119201T (instruction) |
| RS (1) | RS57206B1 (instruction) |
| SG (2) | SG11201607507VA (instruction) |
| SI (1) | SI3119201T1 (instruction) |
| SM (1) | SMT201800268T1 (instruction) |
| WO (1) | WO2015140748A2 (instruction) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2723977T3 (instruction) | 2014-03-19 | 2018-03-10 | ||
| JP6902372B2 (ja) * | 2017-02-28 | 2021-07-14 | ヱスビー食品株式会社 | 苦味抑制用組成物 |
| AU2018397436A1 (en) * | 2017-12-26 | 2020-08-13 | Ftf Pharma Private Limited | Liquid oral formulations for PDE V inhibitors |
| EP3956024A4 (en) * | 2019-04-18 | 2023-01-11 | Ellamed IP & Services Pte. Ltd. | SILDENAFIL CITRATE LIQUID COMPOSITIONS |
| US20220387433A1 (en) * | 2019-11-12 | 2022-12-08 | American Regent, Inc. | Type v phosphodiesterase inhibitor compositions, methods of making them and methods of using them in preventing or treating elevated pulmonary vascular pressure or pulmonary hemorrhages |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994017675A1 (en) * | 1993-02-05 | 1994-08-18 | Kao Corporation | Taste modifying method and bitter taste reducing method |
| US5785984A (en) * | 1993-02-05 | 1998-07-28 | Kao Corporation | Taste-modifying method and bitterness-decreasing method |
| US6548490B1 (en) | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| TWI223598B (en) | 1998-06-22 | 2004-11-11 | Pfizer Ireland Pharmaceuticals | An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate |
| US6531114B1 (en) | 1999-04-06 | 2003-03-11 | Wm. Wrigley Jr. Company | Sildenafil citrate chewing gum formulations and methods of using the same |
| US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| TW200400821A (en) * | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
| EP1237538A2 (en) * | 1999-11-18 | 2002-09-11 | Natco Pharma Limited | An improved pharmaceutical composition for treating male erectile dysfunction |
| RU2277913C2 (ru) | 2000-02-04 | 2006-06-20 | Сео Хонг Ю | Получение водного прозрачного раствора лекарственных форм с желчными кислотами |
| EP1301186A1 (en) | 2000-07-19 | 2003-04-16 | Lavipharm Laboratories, Inc. | Sildenafil citrate solid dispersions having high water solubility |
| US20030216407A1 (en) | 2002-01-31 | 2003-11-20 | Pfizer Inc. | Use of PDE5 inhibitors in the treatment of scarring |
| US7611728B2 (en) | 2003-09-05 | 2009-11-03 | Supernus Pharmaceuticals, Inc. | Osmotic delivery of therapeutic compounds by solubility enhancement |
| US20070065394A1 (en) | 2003-11-17 | 2007-03-22 | Pinney Virginia R | Compositions effective in altering the perception of malodor |
| CN1925860A (zh) * | 2004-01-05 | 2007-03-07 | 特瓦制药工业有限公司 | 制备西地那非碱及其柠檬酸盐的方法 |
| PL1633364T3 (pl) | 2004-01-05 | 2008-07-31 | Teva Pharma | Sposób wytwarzania zasady sildenafilu i cytrynianu sildenafilu |
| US7727565B2 (en) | 2004-08-25 | 2010-06-01 | Cadbury Adams Usa Llc | Liquid-filled chewing gum composition |
| EP1858488B2 (en) | 2005-03-14 | 2022-07-20 | Wyeth LLC | Tigecycline compositions and methods of preparation |
| US7556487B2 (en) | 2006-03-29 | 2009-07-07 | Intergum Gida Sinayi ve Ticaret A.S. | Apparatus for making center-filled chewing gum pieces |
| FR2906140B1 (fr) * | 2006-09-22 | 2008-12-05 | Philippe Perovitch | Forme galenique pour l'administration par voie trans-muqueuse de principes actifs |
| DE502008002360D1 (de) | 2007-06-19 | 2011-03-03 | Symrise Ag | Aromakomposition zum Verringern oder Unterdrücken von unerwünschtem bitteren und adstringierenden Eindruck |
| EP2072044A1 (en) * | 2007-12-19 | 2009-06-24 | Abbott GmbH & Co. KG | Pharmaceutical dosage form comprising a liquid or flowable core composition |
| WO2009125415A1 (en) | 2008-04-07 | 2009-10-15 | Hetero Research Foundation | Amorphous form of sildenafil citrate |
| FR2939321B1 (fr) | 2008-12-05 | 2011-08-26 | Philippe Perovitch | Dispositif de conditionnement et d'administration de principes actifs en solution hydro-alcoolique. |
| US8642270B2 (en) | 2009-02-09 | 2014-02-04 | Vm Institute Of Research | Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer |
| DE102010049708A1 (de) * | 2010-10-28 | 2012-05-03 | Hexal Ag | Orale pharmazeutische Filmformulierung für bitter schmeckende Arzneistoffe |
| EP2787967B1 (en) | 2011-12-05 | 2018-10-31 | Suda Limited | Oral spray formulations and methods for administration of sildenafil |
| GB2497933B (en) | 2011-12-21 | 2014-12-24 | Londonpharma Ltd | Drug delivery technology |
| IN2014KN02583A (instruction) * | 2012-01-18 | 2015-05-08 | Techfields Pharma Co Ltd | |
| WO2014151729A1 (en) | 2013-03-15 | 2014-09-25 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
| NO2723977T3 (instruction) * | 2014-03-19 | 2018-03-10 |
-
2012
- 2012-04-16 NO NO12802846A patent/NO2723977T3/no unknown
-
2015
- 2015-03-19 AU AU2015233006A patent/AU2015233006B2/en not_active Ceased
- 2015-03-19 PL PL15764710T patent/PL3119201T3/pl unknown
- 2015-03-19 CN CN201580013951.5A patent/CN106132204B/zh not_active Expired - Fee Related
- 2015-03-19 MX MX2016012154A patent/MX371276B/es active IP Right Grant
- 2015-03-19 EP EP15764710.8A patent/EP3119201B1/en active Active
- 2015-03-19 KR KR1020167029017A patent/KR20160137584A/ko not_active Ceased
- 2015-03-19 EP EP18161634.3A patent/EP3372083A1/en not_active Withdrawn
- 2015-03-19 LT LTEP15764710.8T patent/LT3119201T/lt unknown
- 2015-03-19 RS RS20180533A patent/RS57206B1/sr unknown
- 2015-03-19 WO PCT/IB2015/052014 patent/WO2015140748A2/en active Application Filing
- 2015-03-19 SM SM20180268T patent/SMT201800268T1/it unknown
- 2015-03-19 EA EA201691871A patent/EA032819B1/ru unknown
- 2015-03-19 SI SI201530249T patent/SI3119201T1/en unknown
- 2015-03-19 HU HUE15764710A patent/HUE038431T2/hu unknown
- 2015-03-19 SG SG11201607507VA patent/SG11201607507VA/en unknown
- 2015-03-19 HR HRP20180773TT patent/HRP20180773T1/hr unknown
- 2015-03-19 ES ES15764710.8T patent/ES2668915T3/es active Active
- 2015-03-19 CA CA2942628A patent/CA2942628C/en active Active
- 2015-03-19 JP JP2016558141A patent/JP6744821B2/ja not_active Expired - Fee Related
- 2015-03-19 PT PT157647108T patent/PT3119201T/pt unknown
- 2015-03-19 SG SG10201808038TA patent/SG10201808038TA/en unknown
- 2015-03-19 DK DK15764710.8T patent/DK3119201T3/en active
-
2016
- 2016-09-14 CL CL2016002318A patent/CL2016002318A1/es unknown
- 2016-09-15 US US15/265,897 patent/US9968609B2/en not_active Expired - Fee Related
- 2016-09-15 IL IL247840A patent/IL247840B/en active IP Right Grant
-
2018
- 2018-04-12 US US15/951,197 patent/US10211534B2/en active Active
- 2018-05-03 CY CY20181100459T patent/CY1120187T1/el unknown
- 2018-10-16 AU AU2018250378A patent/AU2018250378B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010140A (es) | Nuevos metodos. | |
| EA201691151A1 (ru) | Соединения для лечения пациентов с ros1-мутантными раковыми клетками | |
| CL2019002190A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) | |
| CL2016002318A1 (es) | Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| GT201500030A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| GT201500053A (es) | Composicion farmaceutica recubierta que contiene regorafenib | |
| PE20140051A1 (es) | Metodos y productos de farmaco para tratar enfermedad de alzheimer | |
| MA38399A1 (fr) | Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique | |
| CL2015002608A1 (es) | Compuesto de amino-pirazol y usos medicinales relacionados. | |
| MX2021009806A (es) | Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| MX2017003780A (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
| PE20142043A1 (es) | Enfoque metabolico selectivo para aumentar la biodisponibilidad oral de la fenilefrina y otros bioactivos metabolicos | |
| AR091351A1 (es) | Formulaciones de bromocriptina, metodo para mejorar el control glucemico y metodo para la fabricacion | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| CL2015003468A1 (es) | Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d. | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| PE20151300A1 (es) | Composicion antifungica topica para el tratamiento de onicomicosis | |
| AR107298A1 (es) | Método de purificación | |
| AR088845A1 (es) | Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel | |
| AR100153A1 (es) | Medicamento | |
| TW201613600A (en) | Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically |